RVNC

Revance Therapeutics Inc.

Price

return (12m)

p/e

-2.06

p/bv

-2.33

DIVIDEND YIELD

0.00%

RVNC price

Revance Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment RVNC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals RVNC

Valuation

P/E

-2.06

Sector -3.50

Industry -3.50

P/BV

-2.33

Sector 2.01

Industry 2.01

P/Revenue (PSR)

1.54

Sector 2.01

Industry 2.01

EV/EBITDA

-21.54

Sector -223.67

Industry -223.67

EV/EBIT

-20.63

Sector -47.92

Industry -47.92

P/EBITDA

-2.53

Sector -21.50

Industry -21.50

P/EBIT

-2.43

Sector -28.21

Industry -28.21

P/Total Assets

0.82

Sector 1.19

Industry 1.19

P/Net Current Assets

-1.29

Sector -10.26

Industry -10.26

P/Working Capital

1.52

Sector -167.98

Industry -167.98

EPS

-1.77

Sector -1.79

Industry -1.79

BVPS

-1.57

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

72.61%

Sector 41.30%

Industry 41.30%

EBITDA Margin

-47.81%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

-49.90%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

-67.62%

Sector -35.21%

Industry -35.21%

Net Profit Margins

-74.67%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.13

Sector 0.02

Industry 0.02

Profitability

ROE

113.13%

Sector -56.67%

Industry -56.67%

ROA

-39.96%

Sector -59.91%

Industry -59.91%

ROIC

-56.45%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.12

Sector 2.89

Industry 2.89

Net Debt / EBITDA

-8.28

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

-7.93

Sector -8.06

Industry -8.06

Net Debt / Equity

-1.45

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

-2.58

Sector -0.85

Industry -0.85

Equity/Assets

-0.35

Sector 0.46

Industry 0.46

Liabilities/Assets

1.35

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

25.99%

Sector -

Industry -

5Y Earnings CAGR

-8.10%

Sector -

Industry -

Fundamentals RVNC

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
RVNC Revance Therapeutics Inc.	$0.00	-	0.00%	-2.06	-2.33	113.13%	-74.67%
JNJ Johnson & Johnson	$270.61	56.72%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$28.50	26.43%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.75	22.26%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.47	-31.25%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$149.22	93.94%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$164.92	11.31%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.81	43.25%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$70.80	-49.40%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$405.08	45.13%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$798.06	38.86%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$114.66	47.81%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$881.77	19.56%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$523.68	37.91%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.25	46.88%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$952.35	29.68%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$41.31	28.80%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

RVNC Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Revance Therapeutics

Revance Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

27 years

Founded: 1999

2014

Time since IPO - 12 years

470

Employees

Revance Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $379.60 million, with shareholders equity totaling $-163.03 million.

The company employs approximately 470 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Revance Therapeutics Inc. reported $247.01 million in revenue, generating net income of $-184.44 million.

Key financial metrics include a P/E ratio of -2.06, a price-to-book (P/B) ratio of -2.33, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker RVNC.

Market cap

$379.60 million

Net worth

$-163.03 million

$-163,030,000.00

Assets

$461.56 million

$461,560,000.00

Total Shares Outstanding

104.00 million

104,000,000

Average Daily Trading Volume

$3.10 million

$3,096,590.34

Sector

Health Care

Industry

Biotechnology

RVNC

RVNC revenue and profits

Financial Results RVNC

DRAG THE FRAME TO SEE MORE DATA

RVNC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$881.77 16,53% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.25 46,92% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$270.61 56,62% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.75 23,72% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$149.22 94,65% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$164.92 14,08% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$28.50 26,64% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$881.77 16,53% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.25 46,92% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$270.61 56,62% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.75 23,72% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$149.22 94,65% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$164.92 14,08% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$28.50 26,64% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Revance Therapeutics (RVNC) today?

The current price of Revance Therapeutics (RVNC) is $0.00. The stock began the year trading around $0.00 and is currently priced at $0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Revance Therapeutics (RVNC) pay dividends?

Revance Therapeutics (RVNC) did not pay dividends over the past year.

Is Revance Therapeutics (RVNC) a good investment?

Revance Therapeutics (RVNC) is currently trading at $0.00 with a P/E ratio of -2.06. This represents a -381% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Revance Therapeutics (RVNC) stock?

You can buy Revance Therapeutics (RVNC) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol RVNC and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Revance Therapeutics (RVNC) yield today?

Over the past month, Revance Therapeutics (RVNC) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Revance Therapeutics (RVNC) today at the current price of $0.00 your total investment would be $0.00.

Based on historical performance, the investment would have grown to approximately:

$0.00 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

RVNC

Revance Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment RVNC

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING RVNC WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Revance Therapeutics

Revance Therapeutics Inc.

United States

27 years

2014

470

PROFIT X PRICE RVNC

Financial Results RVNC

RVNC cash flow

Asset, Revenue and Profit Growth - RVNC

RVNC balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions